The Effects of Growth Hormone and Insulin-Like Growth Factor-1 Treatments on Hepatic Gene Expression in Obese and Diabetic Mice with Nonalcoholic Fatty Liver Disease
Year: 2010
Type: article
Abstract: Nonalcoholic fatty liver disease (NAFLD), defined as hepatic steatosis with less than 20 g of daily alcohol intake, is the most prevalent liver disease in the world because of its close association with obesity and metabolic disorders. Currently, the only available treatment for NAFLD is diet and exercise. Our lab has found that treatment with growth hormone (GH) or insulin-like growth factor-1 (IGF-1) significantly reduces liver triglyceride content in diet-induced obese and diabetic mice exhibiting NAFLD. The goal of this study was to characterize the molecular mechanisms at the mRNA level of these novel treatments using One-color Agilent 4x44K Whole Mouse Genome Arrays. Two major treatment regimens were used. In treatment regimen #1, mice were subjected to 16 weeks of low-fat (LF) or high-fat (LF) diet, which induces obesity, diabetes, and NAFLD, followed by three weeks (21 days) of twice daily injections. The LF and HF controls received phosphate-buffered saline (PBS). The 3 experimental treatments were GH, IGF-1, and a combination of GH/IGF-1 (Combo). The GH and Combo treatments lowered fat mass and liver triglyceride content, and increased lean mass, plasma IGF-1, and glucose tolerance. The IGF-1 treatment lowered liver triglyceride content and increased lean mass. A subset of four mice from the LF and HF controls and the GH and IGF-1 treated groups were selected for microarray experiment #1 (LF, HF, GH21 & IGF21, respectively). A total of 910, 372, and 256 genes were differentially expressed when comparing HF versus LF, GH21 versus HF, and IGF21 versus HF, respectively.
Author: John Blischak
Institution: Ohio University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2249336710